Bruker [BRKR] vs Abbott Laboratories [ABT] Detailed Stock Comparison
Bruker
NASDAQ
Loading...
Abbott Laboratories
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Bruker wins in 4 metrics, Abbott Laboratories wins in 15 metrics, with 0 ties. Abbott Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Bruker | Abbott Laboratories | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 66.46 | 16.73 | Abbott Laboratories |
| Price-to-Book Ratio | 2.91 | 4.59 | Bruker |
| Debt-to-Equity Ratio | 132.75 | 26.50 | Abbott Laboratories |
| PEG Ratio | 12.75 | 0.46 | Abbott Laboratories |
| EV/EBITDA | 13.78 | 20.82 | Bruker |
| Profit Margin (TTM) | 2.31% | 32.43% | Abbott Laboratories |
| Operating Margin (TTM) | 3.61% | 19.73% | Abbott Laboratories |
| EBITDA Margin (TTM) | 3.61% | 19.73% | Abbott Laboratories |
| Return on Equity | 4.07% | 30.93% | Abbott Laboratories |
| Return on Assets (TTM) | 3.55% | 6.62% | Abbott Laboratories |
| Free Cash Flow (TTM) | $136.00M | $6.35B | Abbott Laboratories |
| Dividend Yield | N/A | 1.28% | N/A |
| 1-Year Return | -44.33% | 14.77% | Abbott Laboratories |
| Price-to-Sales Ratio (TTM) | 1.52 | 5.38 | Bruker |
| Enterprise Value | $7.69B | $238.47B | Abbott Laboratories |
| EV/Revenue Ratio | 2.23 | 5.53 | Bruker |
| Gross Profit Margin (TTM) | 44.88% | 56.44% | Abbott Laboratories |
| Revenue per Share (TTM) | $23 | $25 | Abbott Laboratories |
| Earnings per Share (Diluted) | $0.52 | $7.97 | Abbott Laboratories |
| Beta (Stock Volatility) | 1.20 | 0.70 | Abbott Laboratories |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Bruker vs Abbott Laboratories Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Bruker | -1.81% | 3.16% | 15.23% | -14.70% | -12.77% | -38.90% |
| Abbott Laboratories | -0.56% | 0.24% | 1.03% | 0.07% | 4.94% | 17.52% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Bruker | -44.33% | -34.59% | -14.84% | 99.06% | 140.98% | 687.94% |
| Abbott Laboratories | 14.77% | 32.07% | 21.52% | 215.66% | 422.42% | 551.37% |
News Based Sentiment: Bruker vs Abbott Laboratories
Bruker
News based Sentiment: MIXED
October presented a mixed bag for Bruker, with an earnings miss and lowered guidance countered by new orders, a strategic merger, and continued institutional investment. The conflicting signals create uncertainty, making it a significant but not overwhelmingly positive or negative month for the company.
Abbott Laboratories
News based Sentiment: POSITIVE
Abbott Laboratories delivered strong Q2 earnings and raised its full-year guidance, prompting analyst upgrades and positive sentiment. Strategic partnerships, particularly with Medtronic, and a commitment to shareholder returns further strengthen the investment case, despite a minor price target adjustment due to challenges in China.
Performance & Financial Health Analysis: Bruker vs Abbott Laboratories
| Metric | BRKR | ABT |
|---|---|---|
| Market Information | ||
| Market Cap | $5.24B | $230.73B |
| Market Cap Category | Mid cap | Mega cap |
| 10 Day Avg. Volume | 3,829,870 | 5,941,950 |
| 90 Day Avg. Volume | 4,691,247 | 5,557,987 |
| Last Close | $35.28 | $132.57 |
| 52 Week Range | $28.53 - $65.25 | $110.86 - $141.23 |
| % from 52W High | -45.93% | -6.13% |
| All-Time High | $94.86 (Mar 18, 2024) | $142.60 (Dec 27, 2021) |
| % from All-Time High | -62.81% | -7.03% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.00% | 0.07% |
| Quarterly Earnings Growth | 0.00% | 0.37% |
| Financial Health | ||
| Profit Margin (TTM) | 0.02% | 0.32% |
| Operating Margin (TTM) | 0.04% | 0.20% |
| Return on Equity (TTM) | 0.04% | 0.31% |
| Debt to Equity (MRQ) | 132.75 | 26.50 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $11.89 | $29.05 |
| Cash per Share (MRQ) | $0.65 | $4.18 |
| Operating Cash Flow (TTM) | $165.90M | $9.04B |
| Levered Free Cash Flow (TTM) | $223.20M | $5.92B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.28% |
| Last 12-Month Dividend | N/A | $1.69 |
Valuation & Enterprise Metrics Analysis: Bruker vs Abbott Laboratories
| Metric | BRKR | ABT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 66.46 | 16.73 |
| Forward P/E | 12.75 | 25.84 |
| PEG Ratio | 12.75 | 0.46 |
| Price to Sales (TTM) | 1.52 | 5.38 |
| Price to Book (MRQ) | 2.91 | 4.59 |
| Market Capitalization | ||
| Market Capitalization | $5.24B | $230.73B |
| Enterprise Value | $7.69B | $238.47B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.23 | 5.53 |
| Enterprise to EBITDA | 13.78 | 20.82 |
| Risk & Other Metrics | ||
| Beta | 1.20 | 0.70 |
| Book Value per Share (MRQ) | $11.89 | $29.05 |
Financial Statements Comparison: Bruker vs Abbott Laboratories
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | BRKR | ABT |
|---|---|---|
| Revenue/Sales | $801.40M | $10.36B |
| Cost of Goods Sold | $410.20M | $4.47B |
| Gross Profit | $391.20M | $5.89B |
| Research & Development | $97.10M | $716.00M |
| Operating Income (EBIT) | $65.70M | $1.69B |
| EBITDA | $118.60M | $2.66B |
| Pre-Tax Income | $25.10M | $1.78B |
| Income Tax | $8.70M | $453.00M |
| Net Income (Profit) | $16.80M | $1.33B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | BRKR | ABT |
|---|---|---|
| Cash & Equivalents | $184.20M | $6.53B |
| Total Current Assets | $2.11B | $23.15B |
| Total Current Liabilities | $1.34B | $13.00B |
| Long-Term Debt | $2.08B | $12.74B |
| Total Shareholders Equity | $1.85B | $49.06B |
| Retained Earnings | $2.42B | $47.72B |
| Property, Plant & Equipment | N/A | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | BRKR | ABT |
|---|---|---|
| Operating Cash Flow | $55.70M | $1.42B |
| Capital Expenditures | $-26.00M | $-484.00M |
| Free Cash Flow | $39.00M | $933.00M |
| Debt Repayment | $-175.60M | $-1.00B |
| Common Stock Repurchase | $-10.00M | $-280.00M |
Short Interest & Institutional Ownership Analysis
| Metric | BRKR | ABT |
|---|---|---|
| Shares Short | 12.19M | 18.07M |
| Short Ratio | 2.77 | 3.68 |
| Short % of Float | 0.17% | 0.01% |
| Average Daily Volume (10 Day) | 3,829,870 | 5,941,950 |
| Average Daily Volume (90 Day) | 4,691,247 | 5,557,987 |
| Shares Outstanding | 151.68M | 1.73B |
| Float Shares | 103.14M | 1.73B |
| % Held by Insiders | 0.32% | 0.01% |
| % Held by Institutions | 0.85% | 0.81% |
Dividend Analysis & Yield Comparison: Bruker vs Abbott Laboratories
| Metric | BRKR | ABT |
|---|---|---|
| Last 12-Month Dividend | N/A | $1.69 |
| Last 12-Month Dividend Yield | N/A | 1.28% |
| 3-Year Avg Annual Dividend | N/A | $1.92 |
| 3-Year Avg Dividend Yield | N/A | 0.49% |
| 3-Year Total Dividends | N/A | $5.77 |
| Ex-Dividend Date | N/A | Jan 15, 2025 |